Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Baxter
Mallinckrodt
Johnson and Johnson
Dow

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

KINERET Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Recent Clinical Trials for KINERET

Identify potential brand extensions & biosimilar entrants

SponsorPhase
University of North Carolina, Chapel HillPhase 1/Phase 2
Dutch Cancer SocietyPhase 2
National Heart, Lung, and Blood Institute (NHLBI)Phase 1/Phase 2

See all KINERET clinical trials

Recent Litigation for KINERET

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06
CELGENE CORPORATION v. EMCURE PHARMACEUTICALS LTD.2018-06-28
CELGENE CORPORATION v. SANDOZ INC.2018-06-26

See all KINERET litigation

Pharmacology for KINERET

Company Disclosures: US Patents for KINERET

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 001 2001-11-14   Start Trial Synergen, Inc. (Boulder, CO) 2008-12-24 RX company
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 001 2001-11-14   Start Trial Amgen Inc. (Thousand Oaks, CA) The Regents of the University of Colorado (Boulder, CO) 2020-07-29 RX company
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 001 2001-11-14   Start Trial Amgen Inc. (Thousand Oaks, CA) The Regents of the University of Colorado (Boulder, CO) 2022-02-22 RX company
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 002 2001-11-14   Start Trial Synergen, Inc. (Boulder, CO) 2008-12-24 RX company
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 002 2001-11-14   Start Trial Amgen Inc. (Thousand Oaks, CA) The Regents of the University of Colorado (Boulder, CO) 2020-07-29 RX company
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 002 2001-11-14   Start Trial Amgen Inc. (Thousand Oaks, CA) The Regents of the University of Colorado (Boulder, CO) 2022-02-22 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for KINERET

These patents were identified by searching patent claims

Supplementary Protection Certificates for KINERET

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
SPC/GB10/044 United Kingdom   Start Trial PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR)) HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER.; REGISTERED: UK EU/1/10/618/001 20100526; UK EU/1/10/618/002 20100526; UK EU/1/10/618/003 20100526; UK EU/1/10/618/004 20100526
PA2017038 Lithuania   Start Trial PRODUCT NAME: SARILUMABAS; REGISTRATION NO/DATE: EU/1/17/1196 20170623
CR 2017 00061 Denmark   Start Trial PRODUCT NAME: SARILUMAB; REG. NO/DATE: EU/1/17/1196/001-8 20170627
SZ 23/2002 Austria   Start Trial PRODUCT NAME: ANAKINRA
44/2010 Austria   Start Trial PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 20100526
C300091 Netherlands   Start Trial PRODUCT NAME: ANAKINRA; REGISTRATION NO/DATE: EU/1/02/203/001-004 20020308
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Merck
Mallinckrodt
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.